Prefibrotic Myelofibrosis: An Early-Stage Blood Cancer

Prefibrotic myelofibrosis (pre-PMF) is a chronic blood cancer in which the bone marrow overproduces blood cells but has not yet developed the heavy scarring that defines full-blown myelofibrosis. Recognized as a distinct disease only since the 2016 revision of the World Health Organization’s classification system, pre-PMF sits in a gray zone: it behaves worse than the closely related condition essential thrombocythemia (ET) yet better than overt myelofibrosis, and it is frequently misdiagnosed as one or the other. Understanding what makes it its own entity matters because the risks, the monitoring strategy, and the treatment decisions differ from those of the conditions it mimics.

Why Pre-PMF Was So Recently Defined

For decades, hematologists grouped all forms of primary myelofibrosis together, regardless of how much scarring the bone marrow showed. Meanwhile, many patients whose marrow had little or no scarring were simply labeled with ET because their blood work looked similar: high platelet counts, normal or mildly abnormal white cells, and no obvious symptoms. The problem was that these patients did not behave like typical ET patients over time. They developed blood clots, progressed to heavier fibrosis, and had shorter survival than their ET counterparts.

A landmark international study found that when bone marrow biopsies originally classified as ET were re-examined by expert pathologists, about 16% of cases were reclassified as early or prefibrotic myelofibrosis.¹ That reclassification was not academic hair-splitting. Survival and complication rates were significantly different between the two groups, confirming that the distinction mattered clinically. The 2016 WHO revision formalized pre-PMF as its own category, giving it defined histopathologic features alongside minor clinical criteria such as anemia, elevated white blood cell counts, raised lactate dehydrogenase (LDH), and an enlarged spleen.²

How Pre-PMF Is Diagnosed

The diagnosis rests on what pathologists see in a bone marrow biopsy, not on blood tests alone. That is one reason pre-PMF is so often missed or mislabeled. A routine blood draw showing high platelets looks the same whether you have ET or pre-PMF. The key differences live in the marrow itself.

In pre-PMF, the marrow shows increased cellularity with a particular type of abnormal megakaryocyte, the large cell responsible for producing platelets. These megakaryocytes are not just more numerous; they look wrong under the microscope. They tend to form dense clusters, have oddly shaped nuclei described as “cloud-like” or bulky, and range wildly in size from unusually large to abnormally small.³ Crucially, the marrow at this stage shows no meaningful increase in reticulin or collagen fibers, which is the scarring that defines overt myelofibrosis. The distinction from ET comes down to specific megakaryocyte features: an increased ratio of nucleus to cytoplasm, the cloud-like nuclei, abnormally dark and misshapen nuclei, and clusters that hug the bony struts inside the marrow.⁴

Because these features require expert interpretation, diagnostic accuracy depends heavily on the experience of the pathologist reading the biopsy. In community practice settings where myeloproliferative neoplasms are rare, pre-PMF is the diagnosis most likely to be missed. If you have been told you have ET but your blood counts do not quite fit the textbook picture, or if you are experiencing symptoms that seem out of proportion for ET, a second-opinion biopsy review by a specialist in myeloproliferative diseases is reasonable.

The Mutations Behind It

Like other myeloproliferative neoplasms, pre-PMF is driven by acquired genetic mutations that tell blood-producing stem cells to grow when they should not. The most common is JAK2 V617F, found in roughly two-thirds of pre-PMF patients. CALR mutations account for about a fifth, and MPL mutations are present in a small percentage. Around one in ten patients carry none of these three so-called driver mutations, a status known as “triple-negative.”⁵

These driver mutation frequencies look remarkably similar to those in ET and overt myelofibrosis, which is one reason blood tests alone cannot separate the three conditions. What starts to differ is the burden of additional, non-driver mutations. ASXL1 mutations, for example, were found in about 13% of pre-PMF patients compared with only 3% in ET and 28% in overt myelofibrosis, placing pre-PMF squarely in the middle of a progressive spectrum. Interestingly, though, a study specifically looking at high-molecular-risk mutations in ET and pre-PMF found that these mutations did not significantly affect overall survival within either group on their own.⁶ That finding suggests the diagnosis itself, rather than the mutation profile alone, drives outcome differences between ET and pre-PMF.

How It Differs from ET in Everyday Terms

On paper, pre-PMF and ET can look almost identical at first glance. Both often present with a high platelet count and no obvious symptoms. The 2016 WHO criteria explicitly note that pre-PMF might mimic ET in its presentation.⁷ But there are clinical clues. People with pre-PMF tend to have higher white blood cell counts, lower hemoglobin, higher LDH levels, and more frequently have an enlarged spleen compared with true ET.⁸

More importantly, the disease trajectory differs. Retrospective data consistently show that pre-PMF patients have worse survival than ET patients while doing better than those with overt myelofibrosis.⁹ Pre-PMF patients face higher rates of both blood clots and bleeding, and a greater chance of the disease progressing to either overt fibrosis or acute leukemia.

Blood Clots and Bleeding

This is where pre-PMF gets tricky for both patients and physicians. The condition carries a higher vascular risk than ET despite the two looking similar on initial blood work. One study following more than a thousand patients found that pre-PMF patients had significantly higher 15-year rates of developing blood clots compared with both ET and overt fibrotic myelofibrosis patients. When older age was added to the equation, the difference was stark: patients over 60 with pre-PMF faced a 20-year thrombosis risk of roughly 47%, compared with about 4% for younger ET patients.¹⁰ Venous clots, including unusual ones in abdominal veins, were relatively more common in pre-PMF than in ET.

Bleeding is the other side of the coin. Major bleeding during follow-up occurred at nearly double the rate in pre-PMF patients compared with ET patients. In a study of over 1,100 patients, about 12% of those with pre-PMF experienced major bleeding versus 6% of ET patients. The analysis also found that low-dose aspirin, which is routinely used to prevent clots in ET, actually worsened bleeding in pre-PMF.¹¹ This is a genuinely important finding. A patient incorrectly diagnosed with ET might be placed on aspirin that, if their actual diagnosis is pre-PMF, could do more harm than good.

What Drives Progression to Overt Myelofibrosis

Not everyone with pre-PMF progresses. In a large cohort followed for a median of about seven years, roughly 15% progressed to overt fibrosis and 7% transformed to acute leukemia.¹² Many patients live with stable disease for years or even decades. But identifying who is more likely to progress has become a major focus of research.

A large meta-analysis pooling data from roughly 2,000 patients identified several factors tied to a higher risk of worsening disease or shorter survival. Anemia was the strongest predictor, more than doubling the risk. Age over 65, a white blood cell count above a certain threshold, and the presence of high-molecular-risk mutations were also independently associated with worse outcomes.¹³ Abnormal chromosomes and the appearance of immature blast cells in the blood were additional warning signs in individual studies.

The biology of progression is becoming clearer too. Research using single-cell analysis has shown that certain megakaryocyte populations increase as the disease moves from pre-PMF to overt myelofibrosis, and these cells show rising signals for fibrosis-promoting pathways, including TGF-β and inflammatory cytokines.¹⁴ Separately, blood-based profiling has found that patients with overt myelofibrosis have markedly higher levels of inflammatory mediators like IL-6, IL-1β, and the alarmin S100A8/S100A9 compared with both pre-PMF and ET patients, confirming that inflammation escalates as fibrosis worsens.¹⁵ These findings open the door to potentially using inflammatory marker panels as non-invasive tools to track disease status without repeated bone marrow biopsies.

How Pre-PMF Is Treated

Treatment for pre-PMF is risk-adapted, meaning the approach depends on how aggressive the disease looks in a given person rather than following a one-size-fits-all protocol. For low-risk patients who feel well and have stable blood counts, observation alone is often the starting point. These individuals can have median survival stretching well beyond a decade. Low-dose aspirin may be added if the clotting risk is judged to outweigh the bleeding risk, but as noted above, that calculation is more nuanced in pre-PMF than in ET.¹⁶

When treatment is needed, either because of symptomatic high platelet or white blood cell counts, a prior clotting event, or progression markers, the standard first-line options are hydroxyurea and interferon-alpha. Hydroxyurea is an oral medication that broadly reduces overproduction of blood cells. Interferon-alpha can do the same and has the potential to reduce the size of the mutant cell clone over time, though it requires injections and can cause side effects like fatigue and mood changes.

For patients whose disease has progressed to a higher-risk category with a projected median survival under five years, more intensive management is needed.⁹ JAK inhibitors, most notably ruxolitinib, are used in myelofibrosis to control symptoms, shrink spleens, and improve quality of life, though they do not eliminate the underlying disease. The only potentially curative option remains a stem cell transplant from a matched donor, but transplant carries significant risks of its own, including graft-versus-host disease and treatment-related death, so it is reserved for patients whose disease is progressing despite other therapies.¹⁷

Pre-PMF in Younger Adults

Although myeloproliferative neoplasms are typically diagnosed in middle-aged and older adults, they do occur in younger people. A study of 213 patients with a median age of about 34 found that 16% had early or prefibrotic myelofibrosis rather than ET. Even in this younger group, pre-PMF carried a higher burden of complications. The combined rate of adverse events, including clots, bleeding, and progression to overt myelofibrosis, was significantly higher in those with pre-PMF than in those with ET. No transformation to acute leukemia was observed in either group over a median follow-up of about seven and a half years, which is somewhat reassuring.¹⁸

For younger patients, the diagnosis carries particular weight because the time horizon is so long. A 30-year-old with pre-PMF will live with the disease for decades, during which cumulative risks of clotting, bleeding, and progression accumulate. Interferon-alpha tends to be favored over hydroxyurea in younger patients because of concerns about the long-term effects of hydroxyurea use, including a theoretical but debated risk of promoting leukemic transformation with prolonged exposure. Fertility considerations also enter the picture, as some therapies can affect reproductive health.

The Problem of Misdiagnosis

The fact that roughly one in six patients originally diagnosed with ET turned out to have pre-PMF upon expert biopsy review underscores how frequently this condition is missed. The consequences go beyond labeling. A patient managed as ET when they actually have pre-PMF may not receive appropriately close monitoring for signs of progression, may be given aspirin that increases their bleeding risk, and may not be referred for transplant evaluation when it is warranted.

If you have been diagnosed with ET and have features that do not quite fit, such as a mildly enlarged spleen, LDH levels that keep creeping up, white blood cell counts above normal, or an unexpectedly low hemoglobin, it is worth discussing the possibility of pre-PMF with your hematologist. A biopsy review by a pathologist who regularly evaluates myeloproliferative neoplasms can provide clarity. Getting the right name on the disease is the first step toward getting the right management.

Inflammatory Markers as a Window into Disease Activity

One of the more promising developments in pre-PMF research is the use of blood-based inflammatory and fibrosis markers to characterize where a patient sits on the spectrum from ET to overt myelofibrosis without performing repeated bone marrow biopsies. Researchers have found that levels of inflammatory mediators like IL-6, IL-1β, and the tissue-remodeling marker TIMP1 rise stepwise from ET through pre-PMF to overt myelofibrosis, while certain platelet-derived factors like CXCL4 and the growth factor EGF move in the opposite direction.¹⁵

These profiles are not yet used in routine clinical practice, but they represent a step toward a future where a blood draw could help flag patients whose disease is quietly worsening before it shows up on a biopsy or in standard blood counts. For a disease defined by its bone marrow appearance, the ability to monitor progression non-invasively would be a meaningful practical advance, especially for patients who understandably dread repeated marrow biopsies.